Bria-IMT combined with a checkpoint inhibitor improved overall survival in metastatic breast cancer compared to Trodelvy and chemotherapy. In triple-negative breast cancer, Bria-IMT showed a median ...
Bria-IMT plus a checkpoint inhibitor showed a 52% one-year survival rate in metastatic breast cancer patients, surpassing standard therapy outcomes. The treatment was well-tolerated, with no ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results